 | • レポートコード：QFJ1-4005 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、脊索腫疾患治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（代謝拮抗剤、アントラサイクリン、VEGFR阻害剤、EGFR阻害剤、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・脊索腫疾患治療薬の市場動向 ・企業の競争状況、市場シェア ・脊索腫疾患治療薬の種類別市場規模と予測2016-2027（代謝拮抗剤、アントラサイクリン、VEGFR阻害剤、EGFR阻害剤、その他） ・脊索腫疾患治療薬の用途別市場規模と予測2016-2027（病院、診療所、その他） ・脊索腫疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・脊索腫疾患治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・脊索腫疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・脊索腫疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・脊索腫疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GlaxoSmithKline、Bavarian Nordic、Boehringer Ingelheim International、Pfizer、Merck、Sanofi、Astellas Pharma、AstraZeneca、Amgen、Bristol-Myers Squibb and Company、Novartis、Bayer、Dr. Reddy’s Laboratories、Mylan） ・結論 |
Market Analysis and Insights: Global Chordoma Disease Therapeutics Market
The global Chordoma Disease Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chordoma Disease Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chordoma Disease Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chordoma Disease Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chordoma Disease Therapeutics market.
Global Chordoma Disease Therapeutics Scope and Market Size
Chordoma Disease Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chordoma Disease Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Antimetabolites
Anthracycline
VEGFR Inhibitor
EGFR Inhibitor
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
GlaxoSmithKline
Bavarian Nordic
Boehringer Ingelheim International
Pfizer
Merck
Sanofi
Astellas Pharma
AstraZeneca
Amgen
Bristol-Myers Squibb and Company
Novartis
Bayer
Dr. Reddy’s Laboratories
Mylan
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chordoma Disease Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Antimetabolites
1.2.3 Anthracycline
1.2.4 VEGFR Inhibitor
1.2.5 EGFR Inhibitor
1.2.6 Others
1.3 Market by Application
1.3.1 Global Chordoma Disease Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chordoma Disease Therapeutics Market Perspective (2016-2027)
2.2 Chordoma Disease Therapeutics Growth Trends by Regions
2.2.1 Chordoma Disease Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chordoma Disease Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Chordoma Disease Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Chordoma Disease Therapeutics Industry Dynamic
2.3.1 Chordoma Disease Therapeutics Market Trends
2.3.2 Chordoma Disease Therapeutics Market Drivers
2.3.3 Chordoma Disease Therapeutics Market Challenges
2.3.4 Chordoma Disease Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chordoma Disease Therapeutics Players by Revenue
3.1.1 Global Top Chordoma Disease Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Chordoma Disease Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Chordoma Disease Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chordoma Disease Therapeutics Revenue
3.4 Global Chordoma Disease Therapeutics Market Concentration Ratio
3.4.1 Global Chordoma Disease Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chordoma Disease Therapeutics Revenue in 2020
3.5 Chordoma Disease Therapeutics Key Players Head office and Area Served
3.6 Key Players Chordoma Disease Therapeutics Product Solution and Service
3.7 Date of Enter into Chordoma Disease Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chordoma Disease Therapeutics Breakdown Data by Type
4.1 Global Chordoma Disease Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Chordoma Disease Therapeutics Forecasted Market Size by Type (2022-2027)
5 Chordoma Disease Therapeutics Breakdown Data by Application
5.1 Global Chordoma Disease Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Chordoma Disease Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Chordoma Disease Therapeutics Market Size (2016-2027)
6.2 North America Chordoma Disease Therapeutics Market Size by Type
6.2.1 North America Chordoma Disease Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Chordoma Disease Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Chordoma Disease Therapeutics Market Size by Type (2016-2027)
6.3 North America Chordoma Disease Therapeutics Market Size by Application
6.3.1 North America Chordoma Disease Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Chordoma Disease Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Chordoma Disease Therapeutics Market Size by Application (2016-2027)
6.4 North America Chordoma Disease Therapeutics Market Size by Country
6.4.1 North America Chordoma Disease Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Chordoma Disease Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Chordoma Disease Therapeutics Market Size (2016-2027)
7.2 Europe Chordoma Disease Therapeutics Market Size by Type
7.2.1 Europe Chordoma Disease Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Chordoma Disease Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Chordoma Disease Therapeutics Market Size by Type (2016-2027)
7.3 Europe Chordoma Disease Therapeutics Market Size by Application
7.3.1 Europe Chordoma Disease Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Chordoma Disease Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Chordoma Disease Therapeutics Market Size by Application (2016-2027)
7.4 Europe Chordoma Disease Therapeutics Market Size by Country
7.4.1 Europe Chordoma Disease Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Chordoma Disease Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Chordoma Disease Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Chordoma Disease Therapeutics Market Size by Type
8.2.1 Asia-Pacific Chordoma Disease Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chordoma Disease Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chordoma Disease Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Chordoma Disease Therapeutics Market Size by Application
8.3.1 Asia-Pacific Chordoma Disease Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chordoma Disease Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chordoma Disease Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Chordoma Disease Therapeutics Market Size by Region
8.4.1 Asia-Pacific Chordoma Disease Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chordoma Disease Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Chordoma Disease Therapeutics Market Size (2016-2027)
9.2 Latin America Chordoma Disease Therapeutics Market Size by Type
9.2.1 Latin America Chordoma Disease Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Chordoma Disease Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Chordoma Disease Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Chordoma Disease Therapeutics Market Size by Application
9.3.1 Latin America Chordoma Disease Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Chordoma Disease Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Chordoma Disease Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Chordoma Disease Therapeutics Market Size by Country
9.4.1 Latin America Chordoma Disease Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Chordoma Disease Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chordoma Disease Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Chordoma Disease Therapeutics Market Size by Type
10.2.1 Middle East & Africa Chordoma Disease Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chordoma Disease Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chordoma Disease Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Chordoma Disease Therapeutics Market Size by Application
10.3.1 Middle East & Africa Chordoma Disease Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chordoma Disease Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chordoma Disease Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Chordoma Disease Therapeutics Market Size by Country
10.4.1 Middle East & Africa Chordoma Disease Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chordoma Disease Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Chordoma Disease Therapeutics Introduction
11.1.4 GlaxoSmithKline Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Bavarian Nordic
11.2.1 Bavarian Nordic Company Details
11.2.2 Bavarian Nordic Business Overview
11.2.3 Bavarian Nordic Chordoma Disease Therapeutics Introduction
11.2.4 Bavarian Nordic Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.2.5 Bavarian Nordic Recent Development
11.3 Boehringer Ingelheim International
11.3.1 Boehringer Ingelheim International Company Details
11.3.2 Boehringer Ingelheim International Business Overview
11.3.3 Boehringer Ingelheim International Chordoma Disease Therapeutics Introduction
11.3.4 Boehringer Ingelheim International Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.3.5 Boehringer Ingelheim International Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Chordoma Disease Therapeutics Introduction
11.4.4 Pfizer Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Chordoma Disease Therapeutics Introduction
11.5.4 Merck Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.5.5 Merck Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Chordoma Disease Therapeutics Introduction
11.6.4 Sanofi Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.6.5 Sanofi Recent Development
11.7 Astellas Pharma
11.7.1 Astellas Pharma Company Details
11.7.2 Astellas Pharma Business Overview
11.7.3 Astellas Pharma Chordoma Disease Therapeutics Introduction
11.7.4 Astellas Pharma Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.7.5 Astellas Pharma Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Chordoma Disease Therapeutics Introduction
11.8.4 AstraZeneca Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Chordoma Disease Therapeutics Introduction
11.9.4 Amgen Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.9.5 Amgen Recent Development
11.10 Bristol-Myers Squibb and Company
11.10.1 Bristol-Myers Squibb and Company Company Details
11.10.2 Bristol-Myers Squibb and Company Business Overview
11.10.3 Bristol-Myers Squibb and Company Chordoma Disease Therapeutics Introduction
11.10.4 Bristol-Myers Squibb and Company Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.10.5 Bristol-Myers Squibb and Company Recent Development
11.11 Novartis
11.11.1 Novartis Company Details
11.11.2 Novartis Business Overview
11.11.3 Novartis Chordoma Disease Therapeutics Introduction
11.11.4 Novartis Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.11.5 Novartis Recent Development
11.12 Bayer
11.12.1 Bayer Company Details
11.12.2 Bayer Business Overview
11.12.3 Bayer Chordoma Disease Therapeutics Introduction
11.12.4 Bayer Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.12.5 Bayer Recent Development
11.13 Dr. Reddy’s Laboratories
11.13.1 Dr. Reddy’s Laboratories Company Details
11.13.2 Dr. Reddy’s Laboratories Business Overview
11.13.3 Dr. Reddy’s Laboratories Chordoma Disease Therapeutics Introduction
11.13.4 Dr. Reddy’s Laboratories Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.13.5 Dr. Reddy’s Laboratories Recent Development
11.14 Mylan
11.14.1 Mylan Company Details
11.14.2 Mylan Business Overview
11.14.3 Mylan Chordoma Disease Therapeutics Introduction
11.14.4 Mylan Revenue in Chordoma Disease Therapeutics Business (2016-2021)
11.14.5 Mylan Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chordoma Disease Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Antimetabolites
Table 3. Key Players of Anthracycline
Table 4. Key Players of VEGFR Inhibitor
Table 5. Key Players of EGFR Inhibitor
Table 6. Key Players of Others
Table 7. Global Chordoma Disease Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Chordoma Disease Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Chordoma Disease Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Chordoma Disease Therapeutics Market Share by Regions (2016-2021)
Table 11. Global Chordoma Disease Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Chordoma Disease Therapeutics Market Share by Regions (2022-2027)
Table 13. Chordoma Disease Therapeutics Market Trends
Table 14. Chordoma Disease Therapeutics Market Drivers
Table 15. Chordoma Disease Therapeutics Market Challenges
Table 16. Chordoma Disease Therapeutics Market Restraints
Table 17. Global Chordoma Disease Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Chordoma Disease Therapeutics Market Share by Players (2016-2021)
Table 19. Global Top Chordoma Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chordoma Disease Therapeutics as of 2020)
Table 20. Ranking of Global Top Chordoma Disease Therapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Chordoma Disease Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Chordoma Disease Therapeutics Product Solution and Service
Table 24. Date of Enter into Chordoma Disease Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Chordoma Disease Therapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Chordoma Disease Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Chordoma Disease Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Chordoma Disease Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Chordoma Disease Therapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Chordoma Disease Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Chordoma Disease Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Chordoma Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Chordoma Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Chordoma Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Chordoma Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Chordoma Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Chordoma Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Chordoma Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Chordoma Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Chordoma Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Chordoma Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Chordoma Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Chordoma Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Chordoma Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Chordoma Disease Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Chordoma Disease Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Chordoma Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Chordoma Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Chordoma Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Chordoma Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Chordoma Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Chordoma Disease Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Chordoma Disease Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Chordoma Disease Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Chordoma Disease Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Chordoma Disease Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Chordoma Disease Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. GlaxoSmithKline Company Details
Table 65. GlaxoSmithKline Business Overview
Table 66. GlaxoSmithKline Chordoma Disease Therapeutics Product
Table 67. GlaxoSmithKline Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 68. GlaxoSmithKline Recent Development
Table 69. Bavarian Nordic Company Details
Table 70. Bavarian Nordic Business Overview
Table 71. Bavarian Nordic Chordoma Disease Therapeutics Product
Table 72. Bavarian Nordic Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 73. Bavarian Nordic Recent Development
Table 74. Boehringer Ingelheim International Company Details
Table 75. Boehringer Ingelheim International Business Overview
Table 76. Boehringer Ingelheim International Chordoma Disease Therapeutics Product
Table 77. Boehringer Ingelheim International Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 78. Boehringer Ingelheim International Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Chordoma Disease Therapeutics Product
Table 82. Pfizer Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Merck Company Details
Table 85. Merck Business Overview
Table 86. Merck Chordoma Disease Therapeutics Product
Table 87. Merck Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 88. Merck Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Chordoma Disease Therapeutics Product
Table 92. Sanofi Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Astellas Pharma Company Details
Table 95. Astellas Pharma Business Overview
Table 96. Astellas Pharma Chordoma Disease Therapeutics Product
Table 97. Astellas Pharma Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 98. Astellas Pharma Recent Development
Table 99. AstraZeneca Company Details
Table 100. AstraZeneca Business Overview
Table 101. AstraZeneca Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 102. AstraZeneca Recent Development
Table 103. Amgen Company Details
Table 104. Amgen Business Overview
Table 105. Amgen Chordoma Disease Therapeutics Product
Table 106. Amgen Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 107. Amgen Recent Development
Table 108. Bristol-Myers Squibb and Company Company Details
Table 109. Bristol-Myers Squibb and Company Business Overview
Table 110. Bristol-Myers Squibb and Company Chordoma Disease Therapeutics Product
Table 111. Bristol-Myers Squibb and Company Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 112. Bristol-Myers Squibb and Company Recent Development
Table 113. Novartis Company Details
Table 114. Novartis Business Overview
Table 115. Novartis Chordoma Disease Therapeutics Product
Table 116. Novartis Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 117. Novartis Recent Development
Table 118. Bayer Company Details
Table 119. Bayer Business Overview
Table 120. Bayer Chordoma Disease Therapeutics Product
Table 121. Bayer Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 122. Bayer Recent Development
Table 123. Dr. Reddy’s Laboratories Company Details
Table 124. Dr. Reddy’s Laboratories Business Overview
Table 125. Dr. Reddy’s Laboratories Chordoma Disease Therapeutics Product
Table 126. Dr. Reddy’s Laboratories Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 127. Dr. Reddy’s Laboratories Recent Development
Table 128. Mylan Company Details
Table 129. Mylan Business Overview
Table 130. Mylan Chordoma Disease Therapeutics Product
Table 131. Mylan Revenue in Chordoma Disease Therapeutics Business (2016-2021) & (US$ Million)
Table 132. Mylan Recent Development
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chordoma Disease Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Antimetabolites Features
Figure 3. Anthracycline Features
Figure 4. VEGFR Inhibitor Features
Figure 5. EGFR Inhibitor Features
Figure 6. Others Features
Figure 7. Global Chordoma Disease Therapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Chordoma Disease Therapeutics Report Years Considered
Figure 12. Global Chordoma Disease Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Chordoma Disease Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Chordoma Disease Therapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Chordoma Disease Therapeutics Market Share by Regions (2022-2027)
Figure 16. Global Chordoma Disease Therapeutics Market Share by Players in 2020
Figure 17. Global Top Chordoma Disease Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chordoma Disease Therapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Chordoma Disease Therapeutics Revenue in 2020
Figure 19. Global Chordoma Disease Therapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Chordoma Disease Therapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Chordoma Disease Therapeutics Market Share by Type (2016-2027)
Figure 23. North America Chordoma Disease Therapeutics Market Share by Application (2016-2027)
Figure 24. North America Chordoma Disease Therapeutics Market Share by Country (2016-2027)
Figure 25. United States Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Chordoma Disease Therapeutics Market Share by Type (2016-2027)
Figure 29. Europe Chordoma Disease Therapeutics Market Share by Application (2016-2027)
Figure 30. Europe Chordoma Disease Therapeutics Market Share by Country (2016-2027)
Figure 31. Germany Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Chordoma Disease Therapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Chordoma Disease Therapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Chordoma Disease Therapeutics Market Share by Region (2016-2027)
Figure 41. China Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Chordoma Disease Therapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Chordoma Disease Therapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Chordoma Disease Therapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Chordoma Disease Therapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Chordoma Disease Therapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Chordoma Disease Therapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Chordoma Disease Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. GlaxoSmithKline Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 61. Bavarian Nordic Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 62. Boehringer Ingelheim International Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 64. Merck Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 65. Sanofi Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 66. Astellas Pharma Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 67. AstraZeneca Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 68. Amgen Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 69. Bristol-Myers Squibb and Company Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 70. Novartis Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 71. Bayer Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 72. Dr. Reddy’s Laboratories Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 73. Mylan Revenue Growth Rate in Chordoma Disease Therapeutics Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
世界の上皮成長因子受容体（EGFR）阻害剤市場規模・現状・予測（2021年-2027年） The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is a transmembrane protein that is a receptor for members of the epidermal growth factor family (EGF family) of extracellular protein ligands. The high efficacy of EGFR inhibitors in the treatment of various types of cancer indicati…- 世界の網膜疾患治療薬市場規模・現状・予測（2021年-2027年） Retinal diseases vary widely, but most of them cause visual symptoms. Retinal diseases can affect any part of your retina, a thin layer of tissue on the inside back wall of your eye. Market Analysis and Insights: Global Retinal Disease Therapeutics Market The global Retinal Disease Therapeutics mark…
- 世界の関節疾患治療薬市場規模・現状・予測（2021年-2027年） Joint disease is defined as any type of injury or inflammation or disease that affects the joints of the body. Joint disease can range from acute to very chronic, excruciatingly painful or simply nagging and uncomfortable. Market Analysis and Insights: Global Joint Disease Therapeutics Market The gl…
- 世界の小児呼吸器疾患治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Pediatric Respiratory Disease Therapeutics Market The global Pediatric Respiratory Disease Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in an…
- 世界のバッテン病治療薬パイプライン市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Batten Disease Drug Pipeline Market The global Batten Disease Drug Pipeline market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integri…